Regulation And Legal
Lupin Receives EMA Approval for NaMuscla Pediatric Expansion
Lupin announced EMA approval for NaMuscla expansion to pediatric patients aged 6-17 years with non-dystrophic myotonic disorders.
The approval includes two new dosage strengths (62 mg and 83 mg capsul
